Bendroflumethiazide


Generic Medicine Info
Administration
May be taken with or without food. May be taken w/ food or milk.
Contraindications
Anuria, severe renal and hepatic impairment, symptomatic hyperuricaemia, Addison's disease. Refractory hypokalaemia, hyponatraemia, and hypercalcaemia.
Special Precautions
Patients w/ electrolyte imbalance, DM, gout, mild to moderate hepatic and renal impairment. May exacerbate SLE. Pregnancy and lactation.
Adverse Reactions
Electrolyte imbalance, gout, postural hypotension, GI effects, hyperglycaemia, altered plasma lipid concentration, rashes, photosensitivity, blood disorders, pancreatitis, intrahepatic cholestasis.
C FDA Pregnancy Category C applies to bendroflumethiazide in combination w/ nadolol.
Drug Interactions
Increased serum levels of lithium. Increased nephrotoxicity of NSAID. Increased hypokalaemic effect w/ xanthines, beta-agonists, ACTH, corticosteroids, acetazolamide, carbenoxolone and reboxetine. Enhanced neuromuscular blocking effect of non-depolarising muscle relaxants (e.g. tubocurarine). Postural hypotension may be enhanced by barbiturates, opioids and TCA. Increased risk of hyponatraemia w/ carbamazepine, amphotericin and aminoglutethimide. Increased risk of nephrotoxicity and ototoxicity w/ cisplatin. Reduced absorption by colestipol and colestyramine. Increased risk of ventricular arrhythmias w/ pimozide, thioridazine and terfenadine.
CIMS Class
ATC Classification
C03AA01 - bendroflumethiazide ; Belongs to the class of low-ceiling thiazide diuretics.
Disclaimer: This information is independently developed by CIMS based on bendroflumethiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in